Psoriasis clinical trials at UCLA
6 in progress, 2 open to eligible people
TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
open to eligible people ages 18 years and up
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
Los Angeles, California and other locations
ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
open to eligible people ages 18 years and up
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: - Does ESK-001 reduce the severity of people's psoriasis? - How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: - take drug every day for 24 weeks. - visit the clinic for checkups and tests. - fill out questionnaires about their psoriasis, itch severity, and change in quality of life. - be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. - provide blood and urine samples.
Sylmar, California and other locations
About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Sorry, in progress, not accepting new patients
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 61 weeks.
Los Angeles, California and other locations
JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Sorry, in progress, not accepting new patients
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Santa Monica, California and other locations
CorEvitas Psoriasis (PSO) Registry
Sorry, accepting new patients by invitation only
The primary objective of the CorEvitas Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a North American cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events of special interest, including malignancy, in a real world population of psoriasis patients on new biologic therapies (e.g. secukinumab). Secondary objectives include analyzing the epidemiology and natural history of the disease, comorbidities, current treatment practices, and comparative effectiveness.
JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Sorry, in progress, not accepting new patients
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Los Angeles, California and other locations
Our lead scientists for Psoriasis research studies include April W. Armstrong, MD, MPH.
Last updated: